Frost & Sullivan: New Drug Candidates Hold Tremendous Promise for European HIV Drugs Market
Patients to benefit from potential for improved efficacy in less commonly used types of ARV therapies and one-pill-daily combination drugs
LONDON - 16 April 2013 - The anticipated launch of drugs currently in the pipeline, together with the
introduction of oral combination pills, are set to have a profound impact on the European HIV drugs market.
New analysis from Frost & Sullivan ( http://www.lifesciences.frost.com ), Analysis of the European HIV Drugs Market , finds
that the market earned $5.58 billion in 2012 and estimates this to reach $9.24 billion in 2019. The research covers the most actively used
antiretroviral (ARV) therapies: nucleoside reverse transcriptase inhibitor (NRTI), protease inhibitor (PI), non-nucleoside reverse
transcriptase inhibitor (NNRTI), integrase inhibitors, and other therapeutics (ARV compounds like CCR5 receptor antagonists,
fusion inhibitors, maturation inhibitors, attachment inhibitors and PK boosters).
"In addition to popularly existing therapies like NRTI, NNRTI, PI and integrase inhibitors, new drug candidates over the last decade have
spurred the HIV drugs market," notes Frost & Sullivan Healthcare Research Analyst Deepika Pramod Chopda. "The development of new
candidates, derived from the less commonly used types of ARV therapies like PK boosters, maturation inhibitors, and attachment
inhibitors, is driving the overall market."
With technically advanced features like easy consumption and higher adherence to combination therapy, these candidates assist highly
active antiretroviral therapies (HAART), which are a combination of three or four types of ARV therapies. Their value-added features
and improved efficacy are expected to boost the prospects of less common drug types.
The introduction of one-pill-daily combination drugs will also be a key factor in market development. A reduction in the number of
drugs that need to be consumed directly reduces patient expenditure levels. Other advantages include convenience and ease of consumption.
This trend is poised to have a steady impact on the growth of the HIV drugs market. It is also likely to shift the focus from syringes,
as a source of drug administration, to directly consumable pills.
A major restraint to market expansion remains poor compliance rates due to the absence of established treatment procedures. This can
be offset by improving access to disease awareness campaigns, treatment guidelines, counselling sessions and targeted diagnostics
from health governing bodies.
"Awareness building efforts related to HIV prevention among high-risk groups is increasing," concludes Chopda. "Better understanding
about the need to practice safe-sex, use sterilised needles and conduct blood transfusion in a sterile environment, are also helping
market prospects."
If you are interested in more information on this research, please send an email to Anna Zanchi, Corporate Communications,
at anna.zanchi@frost.com
Analysis of the European HIV Drugs
Market is part of the Life Sciences Growth
Partnership Service programme. Frost & Sullivan's related research services include: European HIV Diagnostics Market and U.S HIV/AIDS
Therapies Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been
evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in
growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with
disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth
strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging
businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership,
please visit http://www.frost.com
Contact
Anna Zanchi
Corporate Communications - Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com
Source: http://www.frost.com/prod/servlet/press-release.pag?docid=276942506&ctxixpLink=FcmCtx1&ctxixpLabel=FcmCtx2
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News
|
